Caribou Biosciences Inc (CRBU) - Total Assets
Based on the latest financial reports, Caribou Biosciences Inc (CRBU) holds total assets worth $179.63 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CRBU total equity for net asset value and shareholders' equity analysis.
Caribou Biosciences Inc - Total Assets Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
Caribou Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Caribou Biosciences Inc's total assets of $179.63 Million consist of 82.8% current assets and 17.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.1% |
| Accounts Receivable | $2.98 Million | 1.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Caribou Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Caribou Biosciences Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Caribou Biosciences Inc's current assets represent 82.8% of total assets in 2025, a decrease from 92.1% in 2019.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2025, down from 66.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Caribou Biosciences Inc Competitors by Total Assets
Key competitors of Caribou Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Caribou Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.71 | 7.16 | 7.02 |
| Quick Ratio | 5.71 | 7.16 | 6.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $119.82 Million | $188.73 Million | $133.72 Million |
Caribou Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Caribou Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.30 |
| Latest Market Cap to Assets Ratio | 1.00 |
| Asset Growth Rate (YoY) | -44.0% |
| Total Assets | $175.37 Million |
| Market Capitalization | $174.79 Million USD |
Valuation Analysis
Near Book Valuation: The market values Caribou Biosciences Inc's assets close to their book value (1.00x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Caribou Biosciences Inc's assets decreased by 44.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Caribou Biosciences Inc (2019–2025)
The table below shows the annual total assets of Caribou Biosciences Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $175.37 Million | -44.03% |
| 2024-12-31 | $313.31 Million | -27.51% |
| 2023-12-31 | $432.21 Million | +15.64% |
| 2022-12-31 | $373.76 Million | -15.51% |
| 2021-12-31 | $442.36 Million | +1127.20% |
| 2020-12-31 | $36.05 Million | -41.80% |
| 2019-12-31 | $61.93 Million | -- |
About Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapse… Read more